|Articles|February 27, 2014

Special Reports

  • NSCLC (Issue 2)
  • Volume 2
  • Issue 1

PD-L1 as a Biomarker for Immunotherapy Agents in Lung Cancer

Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan Kettering Cancer Center, discusses PD-L1 as a potential biomarker for immunotherapy agents for patients with lung cancer.

Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan Kettering Cancer Center, discusses PD-L1 as a potential biomarker for immunotherapy agents for patients with lung cancer.

Read more aboutfrontline treatment considerations for lung cancer > >

Articles in this issue


Latest CME